Overview
ISO 5840-1:2021/Amd 1:2025, titled Cardiovascular implants - Cardiac valve prostheses - Part 1: General requirements - Amendment 1, is an important amendment to the internationally recognized standard governing cardiac valve prostheses. Developed by ISO Technical Committee ISO/TC 150 in collaboration with the European Committee for Standardization (CEN/TC 285), this update refines definitions, testing procedures, and performance criteria vital for cardiovascular implant developers, manufacturers, and regulatory bodies worldwide. The amendment ensures enhanced safety, performance, and reliability of cardiac valve prostheses used in clinical settings.
Key Topics
This amendment introduces critical updates and clarifications to the general requirements for cardiac valve prostheses, including:
- Updated Terms and Definitions
- Revised terminology such as “accessory” (device-specific tool aiding implantation), a detailed definition of “adverse event” encompassing medical occurrences with implant use, and precise characterization of “regurgitant volume”-the backward blood flow through a valve during the cardiac cycle.
- Revised Testing Parameters
- New differential pressure values for aortic, mitral, pulmonary, and tricuspid valves under various blood pressure levels (normotensive to very severe hypertensive) for durability and hydrodynamic performance testing.
- Enhanced protocols for leakage measurement at different back pressures, including specifically tailored test conditions for pediatric subpopulations such as newborns, infants, and adolescents.
- Paediatric Population Considerations
- Updated tables specifying systolic duration, mean arterial pressure, beat rates, cardiac output, and steady flow rates to reflect physiological variations across pediatric age groups, ensuring that implants meet rigorous pediatric safety and functionality standards.
- Test Fixture Improvements
- Allowance for simplified test fixtures in valve testing that simulate physiological conditions more realistically, important for transcatheter and valve-in-valve (ViV) applications.
Applications
ISO 5840-1:2021/Amd 1:2025 serves as an essential reference for:
- Medical Device Manufacturers
Ensuring cardiac valve prostheses meet internationally harmonized design, testing, and performance criteria to achieve regulatory approval and clinical acceptance.
- Regulatory Authorities
Harmonizing evaluation frameworks for safety and efficacy of heart valve substitutes across jurisdictions.
- Clinical Researchers and Cardiologists
Understanding the standards behind valve prostheses used in patients, particularly pediatric cases, to enhance implantation procedures and patient outcomes.
- Testing Laboratories
Utilizing updated testing requirements and protocols to accurately evaluate valve durability, leakage, and hydrodynamics.
Related Standards
- ISO 5840-2:2021 - Covers specific requirements for surgical valve prostheses, complementing Part 1’s general requirements.
- ISO 5840-3:2021 - Focuses on transcatheter valve prostheses, closely linked with the amendments regarding simplified test fixtures and valve deployment protocols in Part 1.
- ISO/IEC Directives Part 1 and Part 2 - Provide procedural and editorial guidelines referenced for standard development and maintenance processes.
Keywords: Cardiac valve prostheses standard, cardiovascular implants ISO, heart valve general requirements, pediatric implant testing, valve prosthesis durability, transcatheter heart valve testing, adverse event cardiac device, regurgitant volume measurement, implantable heart valves, ISO 5840 amendment.
Open preview (PDF)Cardiovascular implants — Cardiac valve prostheses — Part 1: General requirements — Amendment 1
